Panmure Gordon connects leading growth and mid-cap institutional investors with some of the most exciting listed companies. This reach and distribution enables fast-growing corporate and institutional clients achieve their ambitions.

Our research analysts support IPOs and follow-on fundraisings with their relevant and value-added industry and company research.

a selection of client transactions

JULY 2018

Allergy Therapeutics plc

Secondary Offering

Financial Adviser, Nominated Adviser and Broker

£11 million

MAR 2018

Summit Therapeutics plc

Secondary Offering

Joint Broker and Joint Bookrunner

£15 million

FEB 2018

Faron Pharmaceuticals Ov

Secondary Offering

Financial Adviser, Broker and Sole Bookrunner

£15 million

NOV 2017

Keystone Law Group plc

Initial Public Offering raising £15M

Nominated Advisor and Broker

£50 million

OCT 2017

Hutchinson China MediTech Ltd

Secondary Offering


$301 million

JUN 2017

Eland Oil & Gas plc

Secondary Offering

Lead Bookrunner

$20 million

MAY 2017

Blancco Technology Group plc

Secondary Offering

Joint Broker and Joint Bookrunner

£50 million

“Panmure Gordon was professional and proactive – a pleasure to work with, they certainly went the extra mile to deliver a successful IPO. We now have a strong, trusting relationship and appreciate all their support during our early days as a quoted company.”

Doug Doerfler, CEO Maxcyte


Giles Leather

Head of Sales

Andy Sullivan

Head of Sales Trading

Nick Hiley

Head of US Sales